For lung cancers, in particular, there are high failure rates for mutation evaluation (i.e., 32%, 27%, and 35% for EGFR, KRAS, and ALK tests, respectively) with image-guided percutaneous transthoracic core-needle biopsies [22]. This evidence concerns the gene KRAS and lung carcinoma.